SummerHaven Investment Management LLC Acquires 378 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

SummerHaven Investment Management LLC grew its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 1.7% during the 4th quarter, Holdings Channel.com reports. The fund owned 22,704 shares of the biotechnology company’s stock after acquiring an additional 378 shares during the period. SummerHaven Investment Management LLC’s holdings in Arcturus Therapeutics were worth $716,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in Arcturus Therapeutics by 5.9% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,853 shares of the biotechnology company’s stock valued at $277,000 after purchasing an additional 606 shares during the period. MGO One Seven LLC grew its holdings in Arcturus Therapeutics by 4.4% during the 3rd quarter. MGO One Seven LLC now owns 23,688 shares of the biotechnology company’s stock valued at $605,000 after buying an additional 1,000 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Arcturus Therapeutics by 2.6% during the third quarter. Wellington Management Group LLP now owns 43,350 shares of the biotechnology company’s stock valued at $1,108,000 after buying an additional 1,098 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in shares of Arcturus Therapeutics by 3.0% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 43,889 shares of the biotechnology company’s stock worth $1,401,000 after buying an additional 1,272 shares in the last quarter. Finally, New York State Teachers Retirement System bought a new position in shares of Arcturus Therapeutics during the third quarter worth $53,000. Institutional investors own 94.54% of the company’s stock.

Analysts Set New Price Targets

ARCT has been the topic of several research analyst reports. William Blair reiterated an “outperform” rating on shares of Arcturus Therapeutics in a research note on Friday, March 8th. Citigroup lifted their target price on Arcturus Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, February 8th. Finally, HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Arcturus Therapeutics in a report on Wednesday, March 20th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $61.33.

Insiders Place Their Bets

In other Arcturus Therapeutics news, COO Pad Chivukula sold 17,435 shares of the business’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $35.02, for a total transaction of $610,573.70. Following the transaction, the chief operating officer now owns 473,448 shares in the company, valued at $16,580,148.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 13.80% of the stock is owned by insiders.

Arcturus Therapeutics Trading Up 0.3 %

ARCT opened at $26.63 on Tuesday. The stock has a 50-day moving average of $33.53 and a 200 day moving average of $29.90. Arcturus Therapeutics Holdings Inc. has a 12 month low of $17.52 and a 12 month high of $43.81.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.69) by $1.37. Arcturus Therapeutics had a negative return on equity of 18.22% and a negative net margin of 15.65%. The firm had revenue of $33.99 million during the quarter, compared to analysts’ expectations of $64.14 million. On average, analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.83 earnings per share for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.